Autologous stem cell transplantation against systemic sclerosis / high dose treatment with autologous stem cell support, HMAS
Treatment with own (autologous) stem cells has been tested among some of the hardest affected Systemic sclerosis, diffuse form
- Demand is due to the fact that some with systemic sclerosis have particularly poor prognosis with a very serious, rapidly increasing disease course, subsequent manifestations of internal organs, pain, reduced quality of life and early death.
- The treatment is demanding and involves high doses of chemotherapy (cyclophosphamide / Sendoxan) that knock out the immune system. Stem cells previously taken from the person's own blood are given intravenously after chemotherapy
- The body gradually builds up the immune system again. Experiences from systemic sclerosis show the effect of the treatment, but also that up to 10% die after a short time, often related to the drugs in the treatment regimen.
- However, long-term survival (more than 4 years) is better than with other treatments (Sendoxan monthly) when taking into consideration that treatment is given to those with the poorest prognosis. The treatment results are likely to gradually improve with more experience
- In the foreseeable future, the treatment will still be an option for a small proportion of patients with systemic sclerosis
Systemic sclerosis is divided into one begrenset and a diffuse form. The diffuse form is most rare, but often attacks faster and more extensively. Compared to many others Autoimmune diseases we still lack good drug treatment options in systemic sclerosis. The treatment is aimed at stopping disease-related injury to the lungs, heart, kidneys and other internal organs. Drugs that stop skin changes have not yet been developed. Most people with a serious illness in Norway are followed up in cooperation with Rheumatology Department, OUS, Rikshospitalet.
Autologous stem cell treatment
Autologous means that the cells are taken from the patient himself and not from other individuals (this option is called allogeneic). (Transplant from animal to human is called Xero-transplant). The advantage of using own cells (autologous) stem cells is that they are well tolerated and rejections are rare. Thus, immunosuppressive maintenance treatment is not necessary in the same way as by other transplants.
Stem cells are immature cells that can develop into different specialized cells, and they can divide into multiple stem cells. Stem cells can be harvested from bone marrow, fatty tissue or blood. Thus, cells from blood are best suited.
It is very important that all organ functions, including the heart, are thoroughly examined before treatment begins. Both echocardiography and MRI examinations of the heart may be relevant. Latent infections must also be ruled out.
The treatment procedure extends over several phases (according to Van Laar at all 2014)
- Stem cells from bone marrow and blood are "mobilized" (made available) by a growth factor such as Granulocyte colony stimulating (GCSF) factor is given, usually in combination with a chemotherapy (cyclophosphamide /Sendoxan infusions most commonly used). The cellular lymphatic system itself can at the same time affect the rheumatic disease
- Stem cells are collected (harvested) using a laboratory technique (leukoferese) separating stem cells from the blood. Often, leukapheresis is combined with a "immunomagnetic method"
- After the stem cell harvest, the cells are "purified" by immunological techniques such that CD34 + T cells remain. These cells are particularly important for building a new immune system
- The actual disease treatment takes place with extremely large doses of chemotherapy in the form of cyclophosphamide (Sendoxan), (for example, total 200mg / kg intravenously over 4 days)
- To reduce the risk of rejection reaction, antibodies are given (anti-thymocyte globulin) and methylprednisolone (SoluMedrol)
- The harvested CD34 + stem cells are given back as blood infusion
- Over a period of 10 - 20 days, the immune system remains significantly impaired (aplastic phase) with increased risk of infection before it gradually resumes its effect
- Infections including Sepsis (Blood poisoning), viral infections and fungal infections (Aspergillus and more) occur more easily in the weeks following treatment and may be fatal. One checks for example signs of EB virus with PCR technology in the process. Use prevention of antibiotics, antivirals and fungicides is common
- Chemotherapy (cyclophosphamide / Sendoxan) are central to the treatment and is given in high doses
- Nausea and vomiting are common
- Significant hair loss may be expected
- Damage to the heart, kidneys and muscles
- Infertility (inability to have children) as a result of treatment is common
- Increased risk of cancer can occur in the long term
- Inflammation of the mucous membranes in the oral cavity is often painful but rarely life threatening
- Blood clots may occur, but are counteracted by plentiful fluid supply
Scientific basis for autologous stem cell treatment for systemic sclerosis
Current studies completed (per 2018)
- ASTIS study (156 patients): Van Laar 2014)
- ASSIST (19 patients, Lancet 2011)
- SCOT (75 patients, NEMJ 2018)
Autologous stem cell transplant / stem cell support is given as treatment in many autoimmune diseases, such as Multiple sclerosis (MS), Systemic lupus erythematosus (SLE), Myositis, Rheumatoid arthritis (RA), Juvenile arthritis (JIA), Inflammatory bowel disease in addition to systemic sclerosis (Farge D Tyndall A 2010). For many of the diseases, the knowledge of treatment outcomes is limited by the lack of good scientific studies.
- For systemic sclerosis there is a European published study that is a scientifically solid, controlled, phase 3 study. It is based on autologous stem cell transplantation in 79 selected patients with systemic sclerosis Diffuse form and short duration of illness (less than 4 years) and well functioning internal organs. The treatment was compared to chemotherapy (cyclophosphamide / Sendoxan, 12 infusions) given to 77 corresponding patients. The study and treatment results are published (Van Laar et al., JAMA, June 25, Vol. 311, No 24). Patients in the study had been ill on average 1,7 years and 86% had pulmonary exposure. The results showed that 8 deaths (10%) were related to treatment. There were no corresponding deaths in the control group. However, in the long term, stem cell treatment showed better effects on the development of skin symptoms, severe lung, other internal organs, physical function and quality of life. Survival was also better than those receiving other treatments (cyclophosphamide / Sendoxan). Among the eight who died of treatment were seven former smokers. From earlier it is known that smoking is unfavorable to the disease forecast.
- From the United States, treatment is compared to "chemotherapy" in the form of cyclophosphamide (Sendoxan) as an alternative in very severe prognosis. Stem cell treatment appeared to be most effective, but with higher treatment-related mortality (3-6% after 54 and 72 months respectively) (Reference: Sullivan KM, 2018).
- Oslo University Hospital offers in cooperation between Rheumatology department of Oslo University Hospital og Hematological Department treatment to selected patients
- The treatment is risky and offered only a small sample of patients
- It is required, among other things:
- The diagnosis is systemic sclerosis, diffuse form with disease progression and medical examination findings indicating particularly poor prognosis
- Internal organs and immune system are (still) well functioning
- Age under 65 years
- That the patient can withstand / carry out the treatment
Autologous stem cell transplant / stem cell support has been shown to be effective in severe diffuse form of systemic sclerosis
- There is currently no other treatment that has shown equally good effect
- The treatment is offered to selected patients with a diffuse form of systemic sclerosis, a serious disease course, but with the absence of major organ damage
- However, the treatment involves the risk of adverse events that may lead to early death, but with a strict selection of current patients, the complication rate may be reduced
- It may seem that earlier smokers tolerate the treatment the worst (increased mortality)
It is estimated that 1-3 cases in Norway annually may be relevant for autologous stem cell transplant / stem cell support for systemic sclerosis. Corresponding treatment has been given by Multiple myeloma (a malignant blood disease) at Oslo University Hospital for many years.